Multiple region whole-exome sequencing reveals dramatically evolving intratumor genomic heterogeneity in esophageal squamous cell carcinoma

Oncogenesis

Volumn 4, Issue 11, 2015, Pages

  Cao, W ^a   Wu, W ^a,b,f   Yan, M ^a   Tian, F ^a   Ma, C ^a   Zhang, Q ^a   Li, X ^a   Han, P ^a   Liu, Z ^c   Gu, J ^d   Biddle, F G ^e  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF CALGARY   (Canada)

^c Linzhou Cancer Hospital   (China)

^d Meteorological Bureau of Zhengzhou   (China)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EXOME; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; INDEL MUTATION; MOLECULAR CLONING; PHYLOGENY; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR GENE;

EID: 84989352642     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2015.34     Document Type: Article

References (28)

1. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
2. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014; 46: 225-233.
3. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013; 110: 4009-4014.
4. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013; 231: 21-34.
5. Zhang XC, Xu C, Mitchell RM, Zhang B, Zhao D, Li Y et al. Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing. Neoplasia 2013; 15: 1371-1378.
6. Murugaesu N, Wilson GA, Birkbak NJ, Watkins T, McGranahan N, Kumar S et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov 2015; 5: 821-831.
7. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013; 108: 479-485.
8. Seoane J, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. J Intern Med 2014; 276: 41-51.
9. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 2014; 64: 381-387.
10. Song Y, Li L, Ou Y, Gao Z, Li E, Li X et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 2014; 509: 91-95.
11. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 2014; 46: 467-473.
12. Zhang L, Zhou Y, Cheng C, Cui H, Cheng L, Kong P et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet 2015; 96: 597-611.
13. Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 2014; 46: 1097-1102.
14. Yang YL, Chu JY, Luo ML, Wu YP, Zhang Y, Feng YB et al. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 2008; 47: 127-136.
15. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41: 1238-1242.
16. Luo ML, Shen XM, Zhang Y, Wei F, Xu X, Cai Y et al. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 2006; 66: 11690-11699.
17. Hughes AE, Magrini V, Demeter R, Miller CA, Fulton R, Fulton LL et al. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet 2014; 10: e1004462.
18. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.
19. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet 2013; 381: 400-412.
20. Xu L, Li X, Chu ES, Zhao G, Go MY, Tao Q et al. Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival. Gut 2012; 61: 977-985.
21. Wang RJ, Wu P, Cai GX, Wang ZM, Xu Y, Peng JJ et al. Down-regulated MYH11 expression correlates with poor prognosis in stage II and III colorectal cancer. Asian Pac J Cancer Prev 2014; 15: 7223-7228.
22. Liu X, Wang X, Du W, Chen L, Wang G, Cui Y et al. Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemosensitivity and prognosis. Oncotarget 2014; 5: 11681-11694.
23. Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest 2014; 124: 3741-3756.
24. Ma N, Chen F, Shen SL, Chen W, Chen LZ, Su Q et al. MicroRNA-129-5p inhibits hepatocellular carcinoma cell metastasis and invasion via targeting ETS1. Biochem Biophys Res Commun 2015; 461: 618-623.
25. Tan G, Cao X, Dai Q, Zhang B, Huang J, Xiong S et al. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-Activators YAP and TAZ. Oncotarget 2015; 6: 8676-8686.
26. Butrym A, Rybka J, Baczynska D, Tukiendorf A, Kuliczkowski K, Mazur G. Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients. J Exp Clin Cancer Res 2015; 34: 68.
27. Xia B, Yang S, Liu T, Lou G. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Mol Cancer 2015; 14: 57.
28. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 4: 127ps10.